Get the Weekly Intelligence Brief — top committee picks every Sunday.
BDX · NYSE · STOCK

Becton Dickinson (BDX) Stock Analysis

Healthcare Updated August 24, 2026
$190.62
52W $127.59 – $192.30
50/100
$52.90B
57.8
0.26
AI Committee Verdict
Watch
50/100
Conviction: Contested · 33% agreement · 6 analysts
+1.7%
-7.2%
0.23:1
Contested

Is BDX Bullish or Bearish?

Mixed. Innellis AI committee rates Becton Dickinson (BDX) Watch with a composite score of 50/100 , based on 6 analysts with 33% agreement. Last updated August 24, 2026.

What Would Change This View

Upgrade to Buy
Requires a committee score of 60.0 — +9.91 from today. Applies on the first day at or above the line; upgrades are never dampened.
Downgrade to Reduce
Requires the score to fall below 40.0 — -10.09 from today. The band boundary is 45.0, but a one-step downgrade must clear a further margin first. A score oscillating around the line should not change the rating every night.

Executive Summary

The committee is genuinely divided. Macro Analyst sees a compelling case. Value Analyst remains cautious — p/e of 53.2 is expensive by classic value standards. This disagreement is itself the signal — the setup is not clean in either direction.

Bull & Bear Case

Bull Case
  • 3 consecutive earnings beats -- consistent execution — Growth
  • Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
  • MACD histogram positive -- bullish momentum — Technical
  • Weekly trend (sideways) confirms the daily trend -- multi-timeframe agreement — Technical
Bear Case
  • P/E of 53.2 is expensive by classic value standards — Value
  • ROE of only 3.8% -- cheap may mean cheap for a reason — Value
  • Revenue declining -2.6% YoY -- this is not a growth story right now — Growth
  • EPS declining -40.4% YoY despite any revenue growth — Growth
  • RSI at 84 is in overbought territory — Technical
  • Weekly RSI at 81 -- overbought on the larger timeframe too — Technical
Both cases are generated from quantitative data signals, not qualitative or forward-looking judgement. They summarise what the numbers say today.
Price History (6M)

AI Investment Committee

Committee Consensus As of August 24, 2026
Overall Committee Score
50/100
Agreement
33%
Analysts
6
Conviction
Contested
Sector Rank
Top 94%
of 192 Healthcare peers
Value Analyst bearish
35 / 100 · Moderate confidence
Multiples don't clear a genuine value bar here, or cheapness looks justified by weak fundamentals
− P/E of 53.2 is expensive by classic value standards
Growth Analyst neutral
50 / 100 · High confidence
Moderate growth -- present but not remarkable
+ 3 consecutive earnings beats -- consistent execution
− Revenue declining -2.6% YoY -- this is not a growth story right now
Technical Analyst neutral
54 / 100 · High confidence
Mixed or range-bound price action
+ MACD histogram positive -- bullish momentum
− RSI at 84 is in overbought territory
Risk Analyst bearish
35 / 100 · Low confidence
Elevated risk from leverage, volatility, event exposure, or portfolio concentration -- size accordingly
− Bollinger bandwidth of 20.3% signals elevated volatility
Macro Analyst bullish
65 / 100 · Low confidence
Macro backdrop is supportive of risk assets generally, and this name's beta works in its favor
News Analyst bullish
62 / 100 · Low confidence
News flow and recent filings/analyst actions are net positive
Portfolio Manager neutral
45 / 100 · High confidence
Portfolio-level factors are mixed -- worth a deliberate sizing decision, not a default-size position
+ Portfolio position concentration is currently healthy
− Sector concentration is already high (HHI 3063.01)
Open Full Terminal →

Investment Thesis Evolution

Committee score moved marginally from 49.7 to 50.1.

Analyst-level changes:
  • News Analyst: stance neutral->bullish.
  • Portfolio Manager: +1 bearish signal(s).

Comparing 2026-08-23 to 2026-08-24 (1 day apart).

Technical Analysis

RSI (14)
84.2
Overbought
MACD Histogram
0.792
Bullish Momentum
Trend Direction
Sideways
Weekly: Sideways
Market Structure
Lh Ll
Support
$178.14
Resistance
$195.24
Bollinger %B
0.93
Inside Bands
Price vs Moving Averages
EMA 9
$184.30 Above
EMA 21
$176.71 Above
EMA 50
$166.72 Above
EMA 200
$169.37 Above

Fundamental Analysis

Valuation
63
Growth
69
Profitability
38
Financial Health
48
Cash Flow
70
Valuation
P/E Ratio 57.8×
P/B Ratio 2.16×
PEG Ratio -1.43
Dividend Yield 1.95%
52W High $192.30
52W Low $127.59
Quality & Growth
ROE 660.9%
ROA 303.3%
Gross Margin 4612.0%
Operating Margin 982.8%
Revenue Growth YoY
Debt / Equity 0.69
AI Fundamental Assessment
P/E ratio of 57.8 (rich relative to a 15-40x range); Price-to-book of 2.2x; PEG ratio of -1.4 (under 1.0 suggests growth is undervalued relative to price); Return on equity of 6.6%; Return on assets of 3.0%; Net margin of 4.5%; Gross margin of 46.1%; Current ratio of 0.87 (tight short-term liquidity); Debt-to-equity of 0.69; Free cash flow per share is positive (9.48); Most recent quarter beat estimates by 1.8%; 3 consecutive earnings beats; EPS growth accelerating (-0.3% -> +11.4% QoQ); Average YoY EPS growth of -12.2%; Analyst estimates rising over recent quarters
Get the Full BDX Analysis
Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A
Open in Terminal →
Weekly Intelligence Brief
Get the committee's top-scored stocks every Sunday.
Free · No spam · Unsubscribe anytime